Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Healthy Subjects, muscarinic receptor antagonist, propranolol, beta-blocker, beta-agonist
Brief summary
Optimising the propranolol block model
Detailed description
The bronchodilatory effects of inhaled beta2 agonists and anti-muscarinic drugs are the mainstay of symptomatic treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). A new approach is to combine both pharmacological approaches in a single molecule - ie a dual pharmacophore. It will be necessary to explore the relative contribution of the beta2 agonist versus anti-muscarinic bronchodilator properties of such a molecule. One way to do that is to block one of the components. Inhibition of beta2 agonist-mediated bronchodilatation by the non-selective beta-blocker propranolol is an established experimental method. Therefore this method may be useful in exploring the pharmacology of a dual pharmacophore. Published studies have generally looked at the effect of a single dose of propranolol on a beta2 agonist over a relatively short period of time (a few hours). There is a desire to develop long acting bronchodilators that require once daily dosing only. Thus any dual pharmacophore developed is likely to have 24 hour duration of action after a single dose. Therefore to use this method of beta blockade to inhibit beta2 agonist mediated bronchodilation, it is necessary to confirm a dosing regimen of propranolol that has acceptable tolerability and is effective in blocking the effects of a beta2 agonist over 24 hours. That is the main purpose of this study. It is also important to confirm that the bronchodilator effect of an antimuscarinic is unaffected by beta blockade. In addition, it is of interest to examine the bronchodilator effect of a combination of an antimuscarinic and beta2 agonist in healthy volunteers and the effect of propranolol on the combination.
Interventions
DRUGPropranolol
40 mg tablets
DRUGSalbutamol
Metered dose inhaler (600 μg)
DRUGIpratropium
Metered dose inhaler (40 μg)
DRUGPlacebo
Placebo for propranolol tablets
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult male or female aged between 18 and 50 years. * Body mass index within the range 19-29.9 kilograms/metre2 * Forced Expiratory Volume in 1 second (FEV1) \>80% predicted and a FEV1/ Forced Vital Capacity (FVC) ratio \> 0.7 * The subject has an increase in sGAW of \>% over pre-dose baseline within 2 h of administration of 400 ug salbutamol by MDI inhaler at screening or in the 3 months before screening. * Subject has an increase in sGaw of 25% over pre-dose baseline within 2 h following 40 ug ipratropium bromide at screening or in the 3 months before screening * Subjects are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of \< 10 pack years.
Exclusion criteria
* A past or present disease, which as judged by the Investigator and medical monitor may affect the outcome of the study or the safety of the subject * History of respiratory disease * Significant abnormal 12 lead ECG, QTc(B) and QTc(F) value at screening \>450msec on an individual ECG or a PR interval outside the range 120-210 msec * Supine mean heart rate outside the range 45-90 beats per minute (bpm) at screening * Subject has donated a unit of blood within the 56 days or intends to donate within 56 days after completing the study * Subject is currently taking regular (or course of) medication whether prescribed or not (with the exception of contraceptives, including vitamins and herbal remedies such as St John's Wort) * Subject has participated in a clinical study with a New Chemical Entity (NCE) within the past 1 month * Infected with the Hepatitis B, Hepatitis C, or HIV virus * Subject has a history of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specific airway conductance (sGAW) | Pre-dose and up to 26 h post-dose |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability: adverse events, 12 lead ECG, blood pressure and heart rate | Study duration |
| Propranolol pharmacokinetics | Pre-dose and up to 28 h post-dose |
Countries
United Kingdom
Outcome results
None listed